E&Y Report: Big Pharma Loses Edge As Big Biotech Provides More Competition For M&A Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
Big Pharma’s cash is still king, but its crown is slipping as its ability to fund M&A slows. Meanwhile, the smaller players in the industry are starting to make more high-value acquisitions and create more competition for pipeline assets.